Kenvue

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kenvue (KVUE) reports strong Q2 earnings, eyes China growth

Kenvue's Q2 performance showcased robust net sales, organic growth, and strategic investments in key segments. The company's focus on consumer trust, supply chain enhancements, and capital allocation strategy underpin its resilience. Challenges include managing inflationary pressures and sustaining growth post-COVID, but opportunities in China and ongoing investments position Kenvue for future success.

Kenvue (KVUE) reports solid Q3 performance amidst segment challenges

Kenvue (KVUE) delivered a solid Q3 performance, showcasing strength in key segments despite challenges in others.
The company's strategic initiatives, focus on innovation, and outlook for growth opportunities position it well for future success.
Efforts to address challenges in specific segments and capitalize on opportunities demonstrate a proactive approach to sustaining growth and profitability.
Overall positive outlook on third-quarter results reflects the company's strong model, portfolio, and cash flow generation capabilities.

Kenvue reports mixed 2023 performance, focuses on growth strategies

Kenvue's 2023 performance saw organic growth but faced challenges in specific segments, leading to adjustments for 2024. The company aims to drive growth through operational efficiencies, increased brand investments, and a focus on consumer engagement. Challenges in U.S. in-store execution prompted a recovery plan and leadership changes.

Kenvue surpasses Q1 expectations, eyes China growth amid challenges

Kenvue's Q1 performance exceeded expectations, driven by key segments and brands.
Strategic focus on cost optimization, operational efficiency, and brand impact.
Challenges include stabilizing declining segments and managing hyperinflation impact.
Opportunities lie in growing China business, operational reinvention, and new leadership.

Kenvue reports solid Q2 performance and optimistic outlook for 2024

Kenvue's Q2 performance reflects steady growth and improved profitability, driven by strategic initiatives and strong brand performance. While cost management and increased marketing spend pose challenges, the company's focus on brand investment and long-term value creation offers promising opportunities for future growth and shareholder returns.

Kenvue reports Q3 growth, tackles Skin Health challenges, eyes savings

Kenvue's Q3 performance showed organic growth and strong financial metrics.
While facing challenges in the Skin Health segment, the company is focusing on recovery.
Investments in marketing and efficiency improvements highlight growth opportunities.
Executives addressed key questions on guidance, inventory levels, and growth strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kenvue, Inc. is a consumer health company. It operates through the following business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care and hair, sun and others. The Essential Health segment focuses on oral care, baby care, women's health and wound care. The company was founded on February 23, 2022 and is headquartered in Skillman, NJ.

Kenvue Inc shares rose 2.5% in pre-market trading on Monday boosted by an upgrade by Deutsche Bank. The German investment bank has moved the firm, the consumer-health business spun-out of Johnson & Johnson (NYSE:JNJ), to buy from hold with an unchanged price target of $27.

Kenvue oversold, concerns priced in, says Deutsche

Tesla

Hostess Brands

Oracle

J. M. Smucker

Shares of Hostess Brands Inc. TWNK, +0.86% jumped more than 10% after The Wall Street Journal reported late Sunday that J.M. Smucker Co. SJM, +0.88% is close to a roughly $4 billion deal to acquire the snack maker.

Hostess Brands shares rally on deal news and Tesla stock is up on an upgrade, and more moving stocks

The business is home to seven No. 1 brands globally.

Bargain Hunting With $100? This New S&P 500 Dividend Stock Is a No-Brainer to Buy on the Dip

You're familiar with its products, including Tylenol, Neutrogena, Listerine and Johnson's Baby Shampoo. Still, you may not be up to speed on Kenvue Inc. NYSE: KVUE and its status as a long-term dividend payer.

J&J Spinoff Kenvue is the New Dividend Aristocrat on the Block

Kenvue, which was recently spun off from Johnson & Johnson, already pays an attractive dividend. The company supports that payout with a strong financial profile and durable business.

1 Brand-New Dividend Stock Income Investors Won't Want to Miss

Kenvue Incorporated is a leader in the consumer health industry with a large catalog of notable consumer brands. Kenvue has high brand recognition and market share in various sub-sectors of the health industry. Despite initial struggles with costs after the spinoff from Johnson & Johnson, Kenvue is projected to have long-term growth and is a promising stock for investment.

Kenvue: Charting A Healthy Future In Consumer Health

Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) has released new financial results for previous quarters that strip out the consumer-health unit that was recently hived off into a new company called Kenvue. J&J, which is now focused on its pharmaceutical and medical-technology businesses, said second-quarter sales were $21.52 billion, up 6.5% from a year ago.

Johnson & Johnson sets out new guidance after Kenvue split

Johnson & Johnson maintains its quarterly dividend of $1.19 a share after spinning out consumer-health company Kenvue, although it lowers its earnings and sales projections.

Johnson & Johnson Maintains Dividend After Kenvue Spinout

Johnson & Johnson JNJ, +0.01% updated on Wednesday its 2023 financial guidance in the wake of the Kenvue Inc. KVUE, -0.48% separation that was completed last week. The drug maker now expects full-year reported sales of $83.2 billion to $84.0 billion, down from previous guidance of $98.8 billion to $99.8 billion.

J&J revises 2023 sales, profit outlook lower after Kenvue separation, will maintain dividend

Edible Garden AG Inc

To short a stock, traders need to borrow it first and then sell it. Once a stock that is heavily shorted starts to climb, it forces short sellers to buy back the stock and return the shares to the lender.

Short squeeze alert for August 29th: Two stocks ready to soar

Dow member Johnson & Johnson (JNJ) last week completed a split-off exchange offer of 1.53 billion shares of Kenvue Inc (NYSE:KVUE) worth roughly $40 billion.

Options Bulls Pick Up on Blue-Chip's Split-Off

Small investors earned a nice payday of more than $1,000 if they tendered 99 shares of stock in the swap, which expired last week.

J&J's Kenvue Exchange Offer Was a Big Win for the Little Guy

General Motors

Petco Health and Wellness

Autodesk

C3.ai

Ally Financial

Bowlero Corp

Discover

Ford Motor Company

Martin Marietta Materials

Snowflake

Toll Brothers

Vulcan Materials

Walgreens

Williams-Sonoma

Here are some of the tickers on my radar for Thursday, Aug. 24, taken directly from my reporter's notebook.

Here are 16 stocks Jim Cramer is watching, including J&J split-off Kenvue, Petco, GM

Kenvue announced that Wednesday, August 23, marked its first day as a fully independent company after it completed its separation from Johnson & Johnson (NYSE:JNJ). The consumer health company, whose brands include Aveeno, Band-Aid, Listerine, Neutrogena, and Tylenol, was spun off from J&J earlier this year, debuting on the New York Stock Exchange on May 4 for $22 a share.

Kenvue completes separation from J&J ahead of S&P 500 inclusion

Johnson & Johnson investors were able to exchange less than a quarter of their shares for the consumer split off. The company will update financial guidance next week

J&J Makes it Official: Kenvue Stock Swap Offer Was a Huge Hit With Shareholders

Kenvue Inc. KVUE, +3.67% kicks off life as a fully independent public company Wednesday after completing its separation from Johnson & Johnson JNJ, -0.79%, the company said in a release. J&J accepted an aggregate of 191 million shares of its common stock in exchange for 1.53 billion shares of Kenvue's common stock and now owns 9.5% of Kenvue's outstanding shares.

Kenvue becomes ‘fully independent' after final separation from J&J

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”) today announced its separation from Johnson & Johnson, marking its first day as a fully independent company.

Kenvue Becomes a Fully Independent Company Following Final Separation from Johnson & Johnson

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced the final results of its previously announced offer to its shareholders to exchange their shares of Johnson & Johnson common stock for shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) common stock owned by Johnson & Johnson. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on August 18, 2023. Pursuant to the exchange offer, Johnson & Johnson has accepted 190,95.

Johnson & Johnson Announces Final Results of Exchange Offer and Finalizes Separation of Kenvue Inc.

Kenvue (NYSE: KVUE) stock price jumped by more than 3% on Tuesday as investors reacted to the oversubscription of an exchange offer for Johnson & Johnson (NYSE: JNJ). The stock jumped to a high of $23.80, over 6% above the lowest level this year.

Kenvue stock price forecast: Is this JNJ spin-off a good buy?

J&J holders who participated in the exchange offer can choose which J&J shares they want to use for their cost basis in Kenvue.

J&J's Exchange Offer for Kenvue Is Tricky From a Tax Standpoint. What to Do.

Johnson & Johnson (NYSE:JNJ)'s consumer health spinoff Kenvue will replace Advance Auto Parts in the S&P 500 index effective Friday, August 25, the index announced.  This comes after J&J offered to exchange its shares in Kenvue for shares of J&J in a split-off exchange that expired last Friday.

J&J spinoff Kenvue to join S&P 500 on Friday

The action could lift shares of Kenvue, but Johnson & Johnson stock could come under pressure due to index selling.

Kenvue Will Join the S&P 500 Friday. It Could Boost the Stock.

Advance Auto Parts

Emergent BioSolutions

NEW YORK , Aug. 21, 2023 /PRNewswire/ -- Kenvue Inc. (NYSE: KVUE) will replace Advance Auto Parts Inc. (NYSE: AAP) in the S&P 500, and Advance Auto Parts will replace Emergent BioSolutions Inc. (NYSE: EBS) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, August 25. As previously announced on August 9, the addition of Kenvue is the result of S&P 500 and S&P 100 constituent Johnson & Johnson (NYSE: JNJ) offering to exchange the shares of Kenvue held for shares of Johnson & Johnson in a split-off exchange offer that expired on Friday, August 18.

Kenvue Set to Join S&P 500; Advance Auto Parts to Join S&P SmallCap 600

Kenvue Inc. KVUE, +0.13%, the maker of Tylenol and Benadryl, will replace auto-parts retailer Advance Auto Parts Inc. AAP, -2.33% on the S&P 500 Index SPX, +0.69%, S&P Dow Jones Indices said on Monday. The move takes hold before the opening of trading on Friday.

J&J spinoff Kenvue to replace Advance Auto Parts on the S&P 500

Kenvue (NYSE: KVUE ) stock is gaining modestly higher on Monday on the results of a share exchange with Johnson & Johnson (NYSE: JNJ ), from which Kenvue was spun off. Specifically, Johnson & Johnson revealed that the exchange offer was oversubscribed.

News for Kenvue Stock (KVUE)